Grant Retriever

Grant directory

Updated daily. Deadlines shown in UTC; confirm on the official notice.

Reset

451 results · page 15 of 19

FederalDue Jun 16, 2028

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

National Institutes of Health

This notice of funding opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-25-305 "Research Project Grant (Parent R01 Clinical Trial Required)" or its subsequent reissue).

Amount not specifiedOfficial notice ↗
FederalDue Jun 23, 2028

BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) supports transdisciplinary research teams seeking to develop mechanistic, biologically grounded explanations of how neural circuits and their cellular building blocks give rise to central nervous system (CNS) function. Teams must integrate expertise spanning molecular and cellular through systems neuroscience, with strong collaboration between experimental and computational investigators, to bridge cells, circuits, and behavior in a unified framework that yields mechanistic insight.Applications must explicitly connect three core elements: (1) characterization of circuit components (e.g., cell types and/or connectivity); (2) measurement of dynamic circuit activity, incorporating in vivo CNS recordings at cellular and sub-second temporal resolution; and (3) analyses of a tractable behavior or functional output.To address this significant challenge in neuroscience, proposed studies are expected to leverage innovative conceptual or theoretical frameworks, predictive models, and/or cutting-edge approaches that unify these three levels of analysis and bridge experimental and computational components.Recipients are expected to participate in BRAIN consortia activities to identify standards of practice towards multi-level integration.

Up to $8,000,000Official notice ↗
FederalDue Jul 1, 2028

Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) announces the restructured Shared Instrumentation Grant (SIG) Program that consolidates three existing shared-use instrumentation programs, i.e., the Shared Instrumentation Grant program, the High-End Instrumentation Grant program, and the Basic Instrumentation Grant program. The NOFO invites applications from groups of NIH-supported investigators to purchase or upgrade a single state-of-the-art commercially available instrument or an integrated instrumentation system. The instruments purchased through the SIG Program are required to be optimally shared among the users to ensure efficient and cost-effective research operations, enable rigorous and reproducible measurements, and encourage collaborative research and benefit broad research communities at large. The minimum award is $300,000. There is no cap on the total cost of the instrument; however, the maximum award is $5,000,000. Cost sharing is required for premium instruments or special use instruments.

$300,000 – $5,000,000Official notice ↗
FederalDue Jul 1, 2028

Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) aims to build new research capacity and develop a sustainable research program by supporting the purchase of a single commercially available biomedical research instrument currently unavailable in the institution. Instruments funded through this program must be shared among the users to create new research opportunities, enable reproducible data generation, encourage collaborative research and training, and strengthen long-term research capabilities. The minimum award is $50,000. While there is no limit on the total cost of the instrument, the maximum award is $400,000.

$50,000 – $400,000Official notice ↗
FederalDue Jul 7, 2028

Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional)

National Institutes of Health

This NOFO encourages applications for the Lasker Clinical Research Scholars Program. The program supports the research activities of clinical researchers during the early stages of their independent careers as they work to improve human health. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research institute, or can remain as an investigator within the intramural program.

FederalDue Jul 16, 2028

Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)

National Institutes of Health

The goal of the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program is to provide support for early-career clinician-scientists trained in medical or surgical specialties to launch careers as future leaders in aging- or geriatric-focused research. In support of the program's goal, this GEMSSTAR Notice of Funding Opportunity (NOFO) invites applications that propose to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects. The GEMSSTAR program encourages candidates to seek out a supportive research environment to further the program's objectives of fostering the development of early-career clinician-scientists in aging- or geriatric-focused research, particularly as it applies to their clinical specialty/discipline. Toward this end, GEMSSTAR candidates should include a Professional Development Plan that reflects this supportive research environment. In selecting GEMSSTAR recipients, the National Institute on Aging (NIA) will consider the extent to which a candidate's environment is supportive of aging- or geriatric-focused research.

Up to $125,000Official notice ↗
FederalDue Aug 7, 2028

Defense Security Cooperation University - Research Grants

Washington Headquarters Services

The Defense Security Cooperation Agency’s (DSCA) Defense Security Cooperation University (DSCU) promotes access to and production of knowledge on security cooperation. Security cooperation refers to “all Department of Defense (DoD) interactions with foreign security establishments that build and develop allied and partner security capabilities and capacity for self-defense and multinational operations, provide the Armed Forces of the United States with access to the foreign country during peacetime or a contingency operation, and build relationships that promote specific United States security interests” (Joint Publication 3-20, Security Cooperation, 1-2; see also 10 USC § 16, “Security Cooperation”). Evidence-, theory, and data-building activities that contribute to the body of knowledge on security cooperation or irregular warfare, and that result in lessons that can be applied to practice, are the primary focus of this notice of funding opportunity (NFO). Research products sponsored through this NFO must be unclassified and publicly accessible. DSCU expects awardees to participate in conferences, seminars, focus groups and events, and to make final research products and supporting data (if applicable) easily accessible to the public, in order to enhance dissemination of research findings and facilitate application of lessons learned in areas of policy, practice, and workforce professionalization. The DSCU research grant program, conducted pursuant to 10 USC § 4001 and 10 USC § 384(g), is generally open to a broad range of researchers, although individual DSCU components may have restrictions on who may receive grants. Please see the full NFO for complete details.

$2,500 – $800,000Official notice ↗
FederalDue Aug 21, 2028

Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 CT Optional)

National Institutes of Health

The National Institute on Deafness and Other Communication Disorders (NIDCD), with the National Institute of Biomedical Imaging and Bioengineering (NIBIB) aims to support the development and/or adaptation of transformative in vivo high-resolution/high specificity imaging of the human olfactory system. Currently, there are limited non-invasive/minimally invasive technologies available for imaging the living human peripheral and central olfactory system with high spatial and temporal resolution. Imaging the olfactory system in the laboratory and in the clinic is essential to understanding underlying biological mechanisms as well as the etiology of an olfactory disorder. Such imaging has proven challenging due to the olfactory system"s unique anatomical and functional characteristics such as restricted accessibility, multiple cell types, and low signal resolution. Addressing these challenges requires multimodal approaches including leveraging existing advanced tools and technologies and developing new tools tailored for the olfactory system. Recent advances in minimally invasive and non-invasive imaging technologies, such as cell specific biomarkers, fluorescence imaging, specialized endoscopes, optical and acoustic imaging, molecular imaging, and hemodynamic and diffusion imaging have the potential to transform our ability to image and investigate the peripheral and central olfactory system in the living human with superior temporal and spatial resolution and eventually improve diagnostic accuracy of olfactory disorders. Applications must leverage advanced non-invasive/minimally invasive imaging technologies to visualize peripheral (e.g., olfactory- and non-olfactory epithelium) and central olfactory (e.g., olfactory bulb) targets at a level previously unattainable. In addition, projects should engage multidisciplinary teams combining expertise in olfaction, biomedical imaging, biochemistry, bioengineering, and biophysics, as appropriate.

Up to $500,000Official notice ↗
FederalDue Aug 25, 2028

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)

National Institutes of Health

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

Amount not specifiedOfficial notice ↗
FederalDue Sep 4, 2028

Vet-LIRN Capacity-Building Project and Equipment Grants (U18)

Food and Drug Administration

The goal of this NOFO is to fund veterinary diagnostic laboratories in the Vet-LIRN network for grants associated with projects and equipment. Specific objectives include: 1. Supporting the development, adaptation, or verification/validation of new methods associated with animal food issues or antimicrobial resistance. 2. Short-term surveillance or monitoring efforts aligned with the CVM mission. 3. Supporting equipment for testing or developing tests associated with animal food-related issues or antimicrobial resistance, including those for emerging technologies. 4. Developing projects related to antimicrobial stewardship, in alignment with CVM's key initiatives in this area. 5. Contributing as part of Vet-LIRN's AMR monitoring program, including sequencing isolates. 6. Supporting work associated with One Health, including emerging diseases such as COVID-19, when funding is available.

$225,000 – $2,500,000Official notice ↗
FederalDue Sep 25, 2028

Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)

National Institutes of Health

The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.

Amount not specifiedOfficial notice ↗
FederalDue Sep 25, 2028

Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-Designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this NOFO are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

Amount not specifiedOfficial notice ↗
FederalDue Sep 26, 2028

Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals and associated services, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The goal of projects supported by this NOFO is to provide research resources that facilitate optimization and enhancement of scientific rigor, transparency, and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP"s NIH-wide mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Of special interest of the announcement is a requirement of the Center"s close coordination with efforts to develop new approach methodologies (NAMs) that complement traditional animal-based research. These include cell culture, organoids, computational models, and microphysiological systems. Applied Research Component should include studies to generate comparative data to increase applicability of NAMs and promote integration of the most predictive human disease models. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.

Amount not specifiedOfficial notice ↗
FederalDue Sep 28, 2028

Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)

National Institutes of Health

The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing, or improving research models of human health and diseases; developing biology based new approach methodologies (NAMs) applicable to human health and diseases; or improving access to information about or generated from the use of models of human disease. The models, including NAMs, and related biological materials developed must be broadly applicable to the scientific interests of two or more NIH Institutes or Centers (ICs) and must evaluate diseases and processes that impact multiple organ systems in order to align with the ORIP"s NIH-wide mission and programs. Applications must describe the need for and the potential impact of the proposed resources on the research community across a range of scientific disciplines supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research or that do not have a broad impact on the NIH-wide research community will not be accepted. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other ICs will also not be accepted, if submitted in response to this notice of funding opportunity (NOFO).

Amount not specifiedOfficial notice ↗
FederalDue Oct 2, 2028

Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) supports "mature" resources at synchrotron facilities that provide user access to X-ray beamlines for static and dynamic imaging of biological systems ranging from molecules to organs. "Mature" refers to the techniques made available at the resource beamlines, which must be well established and provide utility to the communities they serve without requiring significant novel technology development. Applications may only request support for existing synchrotron resources that are currently supported by NIGMS funding. The facility is expected to be maintained or upgraded to current best practices, make its capabilities and availability known to the biomedical research community through outreach activities, and provide user training and support.This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

Amount not specifiedOfficial notice ↗
FederalDue Oct 6, 2028

BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)

National Institutes of Health

This notice of funding opportunity (NOFO) supports efforts to disseminate resources for integration into neuroscience research practice. The resource(s) should be relevant to the goals of the BRAIN Initiative as outlined in the "BRAIN 2025: A Scientific Vision" and "The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures" and shared broadly to the neuroscience community. The resource(s) should address compelling needs of neuroscience researchers that are otherwise unavailable or impractical in their current form. Activities must include dissemination of an existing resource, and may include one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and/or specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community.

Amount not specifiedOfficial notice ↗
FederalDue Oct 9, 2028

Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this notice of funding opportunity (NOFO) is to support research that advances understanding of the natural history of radiation or chemical exposures; develops relevant injury models; identifies and validates diagnostic tools, biomarkers, or triage technologies; and supports the development of effective medical countermeasures (MCMs) to mitigate or treat acute and/or delayed injuries resulting from radiological/nuclear or chemical public health emergencies.

Amount not specifiedOfficial notice ↗
FederalDue Oct 20, 2028

Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 CT Not Allowed)

National Institutes of Health

The purpose of this Funding Opportunity is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing.This initiative will support secondary data analyses using archived HIV/AIDS data and specimens. The goal of this initiative is to encourage the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology, pathogenesis, treatment, clinical manifestations, and HIV-associated co-infections and co-morbidities in maternal, pediatric and adolescent populations.

Up to $200,000Official notice ↗
FederalDue Nov 2, 2028

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) supports applications to develop and conduct a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or dissemination and implementation science clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, dissemination and implementation science clinical trials and/or prevention strategies.Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This NOFO will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO for a collaborating Data Coordinating Center (PAR-27-013). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement from conceptual design of the intervention through implementation and sustainability and close gaps in health outcomes within the US population and increase health for all.Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Amount not specifiedOfficial notice ↗
FederalDue Nov 2, 2028

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This NOFO will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO (PAR-27-012) for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement plan. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Amount not specifiedOfficial notice ↗
FederalDue Nov 2, 2028

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) supports applications to develop and conduct investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or dissemination and implementation science clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, dissemination and implementation science clinical trials and/or prevention strategies. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, participant recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increase community engagement from conceptual design of the intervention through implementation and sustainability, close gaps in health outcomes within the US population, and increase health for all.

Amount not specifiedOfficial notice ↗
FederalDue Nov 5, 2028

CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit basic research applications to investigate the pathological mechanisms of skin injuries caused by toxic Chemicals of Concern (CoC) identified as public health threats by the United States Government. This NOFO supports the goal of the trans-NIH Chemical Countermeasures Research Program (CCRP) and is intended to spur the discovery and early development of broad-spectrum medical countermeasures (MCMs) to advance the nation's medical and public health preparedness for, response to, and recovery from high consequence chemical disasters and emergencies.

Up to $300,000Official notice ↗
FederalDue Nov 7, 2028

Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

National Institutes of Health

This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that invites applications from eligible organizations to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered. The purpose of this NOFO is to solicit current or recently completed NHLBI K01, K08, K23, and K25 awardees for small grant support to expand their current research objectives or to branch out to a new study emerging from their K award research. This NOFO is intended to facilitate the transition to research independence for these NHLBI K awardees. Current NHLBI K01, K08, K23, and K25 awardees may apply for this R03 support starting in the third year of their K award Project Period. Recently completed NHLBI K01, K08, K23, and K25 award recipients are eligible to apply or resubmit A1 applications if the earliest potential R03 award start date is within two years of the end of their K award Project Period.The R03 grant mechanism supports research projects that can be completed within two years and with limited resources. These projects are expected to generate preliminary data to bolster a subsequent R01-equivalent application. Eligible projects include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or creation of novel experimental model systems.Applicants are required to maintain a minimum of 40% protected research effort during the R03 award period. This requirement can be fulfilled through a combination of effort on the proposed R03 project and other research projects, irrespective of funding source.For current and former K23 awardees, the research proposed in the R03 application may or may not include patient-oriented research.

Up to $85,000Official notice ↗